Aarti Pharmalabs Balance Sheet Health
Financial Health criteria checks 5/6
Aarti Pharmalabs has a total shareholder equity of ₹16.6B and total debt of ₹2.2B, which brings its debt-to-equity ratio to 13.1%. Its total assets and total liabilities are ₹23.1B and ₹6.6B respectively. Aarti Pharmalabs's EBIT is ₹2.8B making its interest coverage ratio 18.7. It has cash and short-term investments of ₹697.7M.
Key information
13.1%
Debt to equity ratio
₹2.17b
Debt
| Interest coverage ratio | 18.7x |
| Cash | ₹697.70m |
| Equity | ₹16.58b |
| Total liabilities | ₹6.56b |
| Total assets | ₹23.13b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AARTIPHARM's short term assets (₹11.7B) exceed its short term liabilities (₹5.6B).
Long Term Liabilities: AARTIPHARM's short term assets (₹11.7B) exceed its long term liabilities (₹965.9M).
Debt to Equity History and Analysis
Debt Level: AARTIPHARM's net debt to equity ratio (8.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AARTIPHARM's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: AARTIPHARM's debt is well covered by operating cash flow (115.7%).
Interest Coverage: AARTIPHARM's interest payments on its debt are well covered by EBIT (18.7x coverage).